journal article·2025-10Open access

D‐glucuronyl C5‐Epimerase Binds to EGFR to Suppress Kidney Fibrosis

Xiaoqi Jing, Jun Wu, Jingru Ning, Xiaoyu Ding, Zhenyun Du, Xiaojiang Wang, Lulin Huang, Ran Wang, Changlin Mei, Kan Ding

Advanced Science· Volume 12· Issue 40

Abstract

Abstract Renal tubular cells actively participate in fibrosis, leading to end‐stage renal failure. However, the key molecules involved in fibrogenesis remain unclear. Glucuronyl C5‐epimerase ( Hsepi , gene name, Glce ) is a key enzyme that catalyzes the biosynthesis of heparan sulfate (HS) chains attached to HS proteoglycans that are ubiquitously located on the cell membrane. Homozygous Glce ‐/‐ mice may exhibit embryonic lethality and multi‐organ defects. However, the role of Glce in kidney fibrosis remains unclear. This study investigated the contribution of Glce to kidney development and its role in renal fibrosis pathogenesis. Here, it shows that Glce expression is significantly attenuated in the kidneys of patients with renal fibrosis and in animal models. Renal tubular‐specific Glce deletion in mice exacerbated kidney fibrosis, while AAV‐mediated Glce overexpression in unilateral ureteral obstruction‐treated mice ameliorated kidney fibrosis via the TGF‐β/Smad2/3 signaling pathway. Mechanistic studies indicate that Glce protein may bind to epidermal growth factor receptor (EGFR) to inactivate EGFR/ERK signaling and further impede TGF‐β/Smad signaling pathway and renal fibrosis in Glce ‐/‐ and wild‐type mice. Notably, the anti‐fibrotic function is independent of Glce enzymatic activation. These findings reveal a novel function of Glce , which plays a key role in kidney fibrosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Chronic Kidney Disease and Diabetes · Renal Diseases and Glomerulopathies · Renal cell carcinoma treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Carbohydrate‐Based Drug Research Center CAS Key Laboratory of Receptor Research State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 China

Department of Nephrology Changzheng Hospital Second Military Medical University Shanghai 201203 China

School of Chinese Materia Medica Nanjing University of Chinese Medicine Nanjing 210023 China

Drug Discovery and Design Center State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 China

Department of Natural Medicine School of Pharmacy Fudan University Shanghai 201203 China

Zhongshan Institute for Drug Discovery Shanghai Institute of Materia Medica Chinese Academy of Science Zhongshan 528400 China

Funding

National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1016/S0140-6736(17)30788-210.1016/S0140-6736(17)30788-2 ↗
2. 10.1038/s41392-023-01379-710.1038/s41392-023-01379-7 ↗
3. 10.1038/s41586-023-06155-910.1038/s41586-023-06155-9 ↗
4. 10.1016/j.cell.2020.09.03310.1016/j.cell.2020.09.033 ↗
5. 10.1021/acscentsci.1c0129310.1021/acscentsci.1c01293 ↗
6. 10.1681/ASN.201305056310.1681/ASN.2013050563 ↗
7. 10.1016/j.bbamcr.2014.06.00510.1016/j.bbamcr.2014.06.005 ↗
8. 10.1074/jbc.M114.55469110.1074/jbc.M114.554691 ↗
9. 10.1074/jbc.M114.60220110.1074/jbc.M114.602201 ↗
10. 10.1074/jbc.M01178320010.1074/jbc.M011783200 ↗
11. 10.1038/nchembio77710.1038/nchembio777 ↗
12. 10.1073/pnas.181833311610.1073/pnas.1818333116 ↗
13. 10.1016/j.jhep.2023.05.01110.1016/j.jhep.2023.05.011 ↗
14. 10.1093/eurheartj/ehv58810.1093/eurheartj/ehv588 ↗
15. 10.1038/s41467-022-34241-510.1038/s41467-022-34241-5 ↗
16. 10.1038/s41586-019-1897-510.1038/s41586-019-1897-5 ↗
17. 10.1038/nm.214410.1038/nm.2144 ↗
18. 10.1038/s41467-023-38771-410.1038/s41467-023-38771-4 ↗
19. 10.1016/j.ebiom.2018.04.02310.1016/j.ebiom.2018.04.023 ↗
20. 10.1080/15548627.2023.228793010.1080/15548627.2023.2287930 ↗
21. 10.1038/s41467-020-15732-910.1038/s41467-020-15732-9 ↗
22. 10.1681/ASN.201812124410.1681/ASN.2018121244 ↗
23. 10.1016/j.carbpol.2022.12019110.1016/j.carbpol.2022.120191 ↗
24. 10.7150/thno.3142410.7150/thno.31424 ↗
25. 10.1681/ASN.201107064510.1681/ASN.2011070645 ↗
26. 10.1093/glycob/cwab01910.1093/glycob/cwab019 ↗
27. 10.2353/ajpath.2010.09101210.2353/ajpath.2010.091012 ↗
28. 10.2353/ajpath.2010.09034510.2353/ajpath.2010.090345 ↗
29. 10.1038/s41581-022-00590-z10.1038/s41581-022-00590-z ↗
30. 10.1093/glycob/cwaa06510.1093/glycob/cwaa065 ↗
31. 10.1016/j.kint.2021.10.02310.1016/j.kint.2021.10.023 ↗
32. 10.1038/s41581-020-00343-w10.1038/s41581-020-00343-w ↗
33. 10.1681/ASN.201308089310.1681/ASN.2013080893 ↗
34. 10.1002/path.296710.1002/path.2967 ↗
35. 10.1038/nrneph.2016.5410.1038/nrneph.2016.54 ↗
36. 10.7150/ijbs.7.105610.7150/ijbs.7.1056 ↗
37. 10.1038/s41581-019-0248-y10.1038/s41581-019-0248-y ↗
38. 10.1038/nm.390110.1038/nm.3901 ↗
39. 10.1038/s41467-020-18304-z10.1038/s41467-020-18304-z ↗
40. 10.1016/j.cmet.2019.08.00310.1016/j.cmet.2019.08.003 ↗
41. 10.1172/JCI021551810.1172/JCI0215518 ↗
42. 10.1038/nm.321810.1038/nm.3218 ↗
43. 10.1016/j.tem.2016.06.00410.1016/j.tem.2016.06.004 ↗
44. 10.3389/fphar.2021.73757010.3389/fphar.2021.737570 ↗
45. 10.3389/fphar.2021.83034010.3389/fphar.2021.830340 ↗
46. 10.1016/j.semcancer.2022.04.00210.1016/j.semcancer.2022.04.002 ↗
47. 10.1038/s41374-017-0015-210.1038/s41374-017-0015-2 ↗